Valeant Pharmaceuticals, under CEO J. Michael Pearson, pursued a strategy of acquiring older drugs and dramatically raising their prices — in some cases by 500% or more. The company cut R&D spending and relied on price increases and acquisitions for growth. Wall Street celebrated the model, and Valeant's stock peaked at over $260.
The strategy collapsed in 2015-2016. Congressional hearings investigated Valeant's pricing practices. A short-seller report questioned its accounting. The company's relationship with a specialty pharmacy (Philidor) raised legal concerns. Revenue growth stalled as political pressure made further price increases untenable.
Valeant's stock fell over 90% from its peak. Pearson was replaced, the company was renamed Bausch Health, and it spent years working through debt and reputational damage. The case illustrated the fragility of a business model built on pricing power that depends on political tolerance.
Cut R&D to fund acquisitions and price hikes; Congress investigated, stock fell 90%, CEO replaced, company renamed.
Valeant's growth model depended on raising drug prices 500%+, which was politically unsustainable.
R&D spending was cut to fund acquisitions, leaving the company with no pipeline of new drugs.
Congressional investigations and public outrage made the pricing strategy politically toxic.
The Philidor specialty pharmacy relationship raised legal and ethical concerns that compounded the crisis.
A business model built on pricing power that depends on political tolerance is a bet on the climate. In healthcare, the climate always shifts.
Valeant was renamed Bausch Health and spent years deleveraging and rebuilding. The case contributed to the broader political debate about drug pricing in the US and influenced pharmaceutical pricing policy discussions.
FOLLOW THE EVIDENCE